Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 48

Sort by

Sort Order Select

Journal Articles

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Lorenzo Falchi, Fritz Offner, Sven de Vos, Joshua Brody, Raul Cordoba, Kim Linton, Sylvia Snauwaert, Michael Roost Clausen, Toshihiko Oki, Andrew J. Steele, Yi Hao, Kimberly G. Archer, Ali Rana, David Belada

Blood (2024) 144 (Supplement 1): 581.

https://doi.org/10.1182/blood-2024-198023

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Blood (2024) 144 (Supplement 1): 342.

https://doi.org/10.1182/blood-2024-200262

Published: 2024

Journal Articles

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

Neha Dixit, Binhuan Wang, Kevin Zhao, Catherine Thieblemont, Irit Avivi Mazza, David Lavie, Abraham Avigdor, Carlos Grande Garcia, Andrew J. Steele, Mostafa Seliem, Pegah Jafarinasabian, Edith Szafer Glusman

Blood (2024) 144 (Supplement 1): 1734.

https://doi.org/10.1182/blood-2024-200395

Published: 2024

Journal Articles

Continuous or Fixed-Duration Treatment for CD3xCD20 Bispecifics: A Modeling and Simulation Study Using Epcoritamab Monotherapy

Xiaozhi Liao, Tommy Li, Steven Xu, Mohamed-Eslam F Mohamed, Mahipal Sinnollareddy, Manish Gupta, Monica Wielgos-Bonvallet, Andrew J. Steele, Mariana Sacchi, Yanguang Cao

Blood (2024) 144 (Supplement 1): 1701.

https://doi.org/10.1182/blood-2024-205552

Published: 2024

Journal Articles

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Joshua Brody, Lorenzo Falchi, Umberto Vitolo, Marcel Nijland, Fritz Offner, Sylvia Snauwaert, Poliana Patah, Jennifer Marek, Christopher Morehouse, Andrew J. Steele, Yi Hao, Daniela Hoehn, Kim Linton

Blood (2024) 144 (Supplement 1): 1627.

https://doi.org/10.1182/blood-2024-200369

Published: 2024

Journal Articles

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

Tycel J. Phillips, Michael Roost Clausen, Wojciech Jurczak, Tae Min Kim, Kim Linton, Chan Y Cheah, Jieying Jiang, Kubra Karagoz, Mohammad Atiya, Christian Eskelund, Han Si, Edith Szafer Glusman, Andrew J. Steele, Charles Kearns, Catherine Thieblemont

Blood (2024) 144 (Supplement 1): 3115.

https://doi.org/10.1182/blood-2024-199799

Published: 2024

Journal Articles

Epcoritamab Induces in Vitro-Derived Terminally Differentiated Exhausted T Cells to Kill B Cells

Daisy Lin, Vanessa Spires, Jeremy Gale, Nathan Cheadle, Tine Casneuf, Gregg Masters, Lisa Grimm, Omar Jabado, Tahamtan Ahmadi, Mark Fereshteh, Maria Jure-Kunkel, Andrew J. Steele, Jordan Blum

Blood (2024) 144 (Supplement 1): 2998.

https://doi.org/10.1182/blood-2024-208250

Published: 2024

Journal Articles

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Blood (2024) 144 (Supplement 1): 4480.

https://doi.org/10.1182/blood-2024-198714

Published: 2024

Journal Articles

Trial in Progress: A Phase 2 Study of Linvoseltamab for the Treatment of High-Risk Smoldering Multiple Myeloma (LINKER-SMM1)

Paula Rodriguez Otero, Maria-Victoria Mateos, Oluwaseun Aina, Arijit Sinha, Andrew J Steele, Anasuya Hazra, Karen Rodriguez Lorenc, Glenn S. Kroog, Shawn M Sarkaria, Jesus San Miguel

Blood (2023) 142 (Supplement 1): 3393.

https://doi.org/10.1182/blood-2023-179356

Published: 2023

Journal Articles

Phagocytosing with TP53 and extracellular vesicles

Andrew J. Steele

Blood (2022) 139 (25): 3565–3566.

https://doi.org/10.1182/blood.2022016100

Published: 2022

Journal Articles

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Blood (2019) 134 (Supplement_1): 1752.

https://doi.org/10.1182/blood-2019-128899

Published: 2019

Journal Articles

Roring ahead with DOCK2

Andrew J. Steele

Blood (2018) 132 (2): 115–116.

https://doi.org/10.1182/blood-2018-05-848382

Published: 2018

Journal Articles

PI3Kδ/AKT Inhibition Augments 2-Phenylethynesulfonamide Induced Apoptosis Via the Unfolded Protein Response in Chronic Lymphocytic Leukemia

Matthew D Blunt, PhD, Lindsay D Smith, PhD, Adam Linley, PhD BSc, Jonathan C Strefford, PhD, Peter Johnson, Francesco Forconi, MD DM, PhD FRCPath, Freda K. Stevenson, DPhil, Graham Packham, PhD, Andrew J Steele, PhD

Blood (2017) 130 (Supplement 1): 4290.

https://doi.org/10.1182/blood.V130.Suppl_1.4290.4290

Published: 2017

Journal Articles

The Contribution of Gene Mutations to Long-Term Clinical Outcomes: Data from the Randomised UK LRF CLL4 Trial

Blood (2017) 130 (Supplement 1): 259.

https://doi.org/10.1182/blood.V130.Suppl_1.259.259

Published: 2017

Journal Articles

Regulation and Impact of BCR Induced Autophagy in Chronic Lymphocytic Leukemia

Lindsay D Smith, PhD, Laura I Karydis, PhD, Margaret Ashton-Key, MD, Jonathan C Strefford, PhD, Freda K. Stevenson, DPhil, Graham Packham, PhD, Mark Cragg, PhD, David A Tumbarello, PhD, Matthew D Blunt, PhD, Francesco Forconi, MD DM, PhD FRCPath, Andrew J Steele, PhD

Blood (2017) 130 (Supplement 1): 1717.

https://doi.org/10.1182/blood.V130.Suppl_1.1717.1717

Published: 2017

Journal Articles

Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy

Blood (2017) 130 (Supplement 1): 56.

https://doi.org/10.1182/blood.V130.Suppl_1.56.56

Published: 2017

Journal Articles

Releasing the brakes on BTK-targeting miRNA

Matthew D. Blunt, Andrew J. Steele

Blood (2016) 128 (26): 3023–3024.

https://doi.org/10.1182/blood-2016-11-748145

Published: 2016

Journal Articles

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Matthew D Blunt, PhD, Rachel Dobson, BSc(Hons), Lindsay D Smith, PhD, Jonathan C. Strefford, Pamela B. Conley, PhD, Anjali Pandey, PhD, Andrew J Davies, FRCP PhD, Peter M Johnson, MA, MD, Graham Packham, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath, Greg P Coffey, PhD, Andrew J Steele, PhD

Blood (2016) 128 (22): 351.

https://doi.org/10.1182/blood.V128.22.351.351

Published: 2016

Journal Articles

Global and MYC-Specific Translation Is Enhanced in Activated Chronic Lymphocytic Leukemia Cells Carrying NOTCH1 C.7541_7542delct Mutations

Annalisa D'Avola, MSc, Alison Yeomans, PhD, Samantha Drennan, PhD, Matthew Rose-Zerilli, PhD, Jonathan C. Strefford, Freda K Stevenson, DPhil, Andrew J Steele, PhD, Graham Packham, PhD, Francesco Forconi, MD DM, PhD FRCPath

Blood (2016) 128 (22): 970.

https://doi.org/10.1182/blood.V128.22.970.970

Published: 2016

Journal Articles

Early Enhancement of IgM Expression and Signaling Capacity during Ibrutinib Therapy in CLL Patients

Samantha Drennan, PhD, Giorgia Chiodin, MS, Annalisa D'Avola, MSc, Peter W Johnson, MD, Livio Trentin, MD, Graham Packham, PhD, Andrew J Steele, PhD, Freda K Stevenson, DPhil, Francesco Forconi, MD DM, PhD FRCPath

Blood (2016) 128 (22): 4381.

https://doi.org/10.1182/blood.V128.22.4381.4381

Published: 2016

NARROW

Fixed-Duration Epcoritamab + R-CHOP Induces High Complete Response Rates in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Withhigh-Risk Features: Long-Term Results from the Epcore NHL-2 Trial

Fixed-Duration Epcoritamab + R 2 Drives Deep and Durable Responses in Patients with Relapsed or Refractory Follicular Lymphoma: 2-Year Follow-up from Arm 2 of the Epcore NHL-2 Trial

Immune Biomarkers of Mechanism of Action of Epcoritamab (Epcor) Plus Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (pola-R-CHP) in Frontline DLBCL

Continuous or Fixed-Duration Treatment for CD3xCD20 Bispecifics: A Modeling and Simulation Study Using Epcoritamab Monotherapy

Fixed-Duration Epcoritamab in Combination with Bendamustine + Rituximab for First-Line Treatment of Follicular Lymphoma: Initial Results from Epcore NHL-2 Arm 3

Prior Bendamustine (Benda) Exposure Did Not Impact Clinical Outcomes and Decreased CD4+ but Not CD8+ T-Cells in Patients with Diffuse Large B-Cell Lymphoma (DLBCL) Treated with the Bispecific Antibody Epcoritamab (Epcor)

Epcoritamab Induces in Vitro-Derived Terminally Differentiated Exhausted T Cells to Kill B Cells

3-Year Update from the Epcore NHL-1 Trial: Epcoritamab Leads to Deep and Durable Responses in Relapsed or Refractory Large B-Cell Lymphoma

Trial in Progress: A Phase 2 Study of Linvoseltamab for the Treatment of High-Risk Smoldering Multiple Myeloma (LINKER-SMM1)

Phagocytosing with TP53 and extracellular vesicles

High Surface IgM Levels Associate with Shorter Response Duration and Bypass of the BTK Blockade during Ibrutinib Therapy in CLL Patients

Roring ahead with DOCK2

PI3Kδ/AKT Inhibition Augments 2-Phenylethynesulfonamide Induced Apoptosis Via the Unfolded Protein Response in Chronic Lymphocytic Leukemia

The Contribution of Gene Mutations to Long-Term Clinical Outcomes: Data from the Randomised UK LRF CLL4 Trial

Regulation and Impact of BCR Induced Autophagy in Chronic Lymphocytic Leukemia

Clinical Importance of DNA Methylation Signatures in Chronic Lymphocytic Leukaemia Patients Treated with Chemo-Immunotherapy

Releasing the brakes on BTK-targeting miRNA

Regulation of B-Cell Receptor Signalling By the Tumour Microenvironment in Chronic Lymphocytic Leukemia (CLL) and Its Impact on Adhesion and miRNA Expression

Global and MYC-Specific Translation Is Enhanced in Activated Chronic Lymphocytic Leukemia Cells Carrying NOTCH1 C.7541_7542delct Mutations

Early Enhancement of IgM Expression and Signaling Capacity during Ibrutinib Therapy in CLL Patients

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only